CGTX Stock Overview
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cognition Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.93 |
| 52 Week High | US$3.49 |
| 52 Week Low | US$0.90 |
| Beta | 1.62 |
| 1 Month Change | 5.46% |
| 3 Month Change | -19.58% |
| 1 Year Change | 12.87% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -84.89% |
Recent News & Updates
Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's
Apr 18Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
Nov 30
Recent updates
Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's
Apr 18Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
Nov 30Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
Aug 15Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans
Mar 17Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study
Sep 27We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth
Aug 12Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar
Aug 05We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Mar 19Shareholder Returns
| CGTX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.9% | 0.08% | 1.2% |
| 1Y | 12.9% | 13.2% | 24.9% |
Return vs Industry: CGTX matched the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: CGTX underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| CGTX volatility | |
|---|---|
| CGTX Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CGTX's share price has been volatile over the past 3 months.
Volatility Over Time: CGTX's weekly volatility has decreased from 14% to 8% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 27 | Lisa Ricciardi | www.cogrx.com |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer’s disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
Cognition Therapeutics, Inc. Fundamentals Summary
| CGTX fundamental statistics | |
|---|---|
| Market cap | US$75.27m |
| Earnings (TTM) | -US$25.79m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs CGTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$25.79m |
| Earnings | -US$25.79m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.66 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 2.2% |
How did CGTX perform over the long term?
See historical performance and comparison